Working... Menu

Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02183233
Recruitment Status : Terminated
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The aim of this trial was to assess the efficacy and safety of Eschscholtzia Californica (EC) in treating patients having psycho-physiologic insomnia in a double-blind randomised placebo controlled trial during a 28-day treatment duration.

Condition or disease Intervention/treatment Phase
Sleep Initiation and Maintenance Disorders Drug: Eschscholtzia Californica Drug: Eschscholtzia Californica Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind Randomized, Placebo Controlled Study to Assess the Efficacy and the Safety of Eschscholtzia Californica 1000 mg Per Day in Treating Primary Insomnia During a 28 Day Treatment Duration.
Study Start Date : January 1998
Actual Primary Completion Date : June 1998

Arm Intervention/treatment
Experimental: Eschscholtzia Californica Drug: Eschscholtzia Californica
Placebo Comparator: Eschscholtzia Californica Placebo Drug: Eschscholtzia Californica Placebo

Primary Outcome Measures :
  1. Change from baseline in sleep latency [ Time Frame: Days 0, 7, 14 and 28 ]

Secondary Outcome Measures :
  1. Change from baseline in sleep duration [ Time Frame: Days 0, 7, 14 and 28 ]
  2. Change from baseline in number of awakenings [ Time Frame: Days 0, 7, 14 and 28 ]
  3. Change from baseline in quality of sleep [ Time Frame: Days 0, 7, 14 and 28 ]
  4. Change from baseline in presence of morning sleepiness [ Time Frame: Days 0, 7, 14 and 28 ]
  5. Change from baseline in morning concentration ability [ Time Frame: Days 0, 7, 14 and 28 ]
  6. Change from baseline in Clinical Global Impression (CGI) score [ Time Frame: Days 0, 7, 14 and 28 ]
  7. Change from baseline in quality of life (QL questionnaire SF-23) [ Time Frame: Days 0, 7, 14 and 28 ]
  8. Number of patients with adverse events [ Time Frame: up to 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female above 18 or below 65 years old
  • Diagnosis of psycho-physiologic insomnia, according to the criteria of DSM-IV (Diagnostic and Statistical manual - Version IV)
  • Written informed consent

Exclusion Criteria:

  • Patient who is already taking other investigational drugs or who has taken part in another trial during the past three months
  • Patient who has an history of psychiatric diseases, such as:

    • anxiety disorders; the score of the HAMA (Hamilton anxiety scale) must be < 10
    • depression according to the DSM IV criteria; the score of the HAMD (Hamilton depression scale) must be < 10
    • mania
    • schizophrenia
    • dementia
  • Patient who has an history of neurologic diseases, such as:

    • Parkinson syndrome
    • crania cerebral trauma post syndrome
    • brain tumor
    • fibromyalgia
  • Patient who has an history of an iatrogenic insomnia, due to drugs like antidepressor, neuroleptic or benzodiazepine, hypnotic
  • Patient with an hypersomnia or a sleep apnea syndrome
  • Patient with any pathology inducing a chronic pain, a pyrosis, a nocturnal pollakiuria, a dyspnea
  • Patient with a Restless Leg Syndrome
  • Patient with severe hepatic or renal insufficiency which judged to be regarded as clinically relevant by the investigator, or any known clinically significant disease which may induce a risk for the patient in participating to the trial
  • Breast feeding or pregnant female, or female with no efficient contraception method
  • Patient with non-stabilised thyroid dysfunction
  • Patient with a known allergy to Eschscholtzia Californica or its compounds
  • Patient with alcohol or drug dependency
  • Patient drinking tea, coffee or Coca-Cola after 4 p.m.

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02183233     History of Changes
Other Study ID Numbers: 1120.2
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders